331-345 of 825
Mind Matters: Psychiatric Comorbidity in the Prodromal Phase of MS
NeuroFrontiersMind Matters: Psychiatric Comorbidity in the Prodromal Phase of MS
Charles Turck, PharmD, BCPS, BCCCP
Anibal Chertcoff, MD
Examining Emerging Gut Microbiota Biomarkers for MS
NeuroFrontiersExamining Emerging Gut Microbiota Biomarkers for MS
MS in Children: Exploring Biomarker Research Advancements
NeuroFrontiersMS in Children: Exploring Biomarker Research Advancements
Ahmed Abdelhak, MD
Discussing Disparities in MS Care for Underrepresented Populations
NeuroFrontiersDiscussing Disparities in MS Care for Underrepresented Populations
Charles Turck, PharmD, BCPS, BCCCP
Tirisham V. Gyang, MD
Gopika Govindan Kutty, MD
- advertisement
Discussing the Latest in MS Treatment and Disease-Modifying Therapies
NeuroFrontiersDiscussing the Latest in MS Treatment and Disease-Modifying Therapies
Charles Turck, PharmD, BCPS, BCCCP
Jay Avasarala, MD, PhD
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Craig Chepke, MD, FAPA
A New Hope for Patients with MS – The First FDA-Approved Biosimilar
NeuroFrontiersA New Hope for Patients with MS – The First FDA-Approved Biosimilar
Diagnosing Suspected MS: A Review of the Updated Guidelines
NeuroFrontiersDiagnosing Suspected MS: A Review of the Updated Guidelines
Andrew Wilner, MD, FACP, FAAN
Eoin Flanagan, MB, BCh
The Hidden Struggles of Tardive Dyskinesia: Improving Patient Care
NeuroFrontiersThe Hidden Struggles of Tardive Dyskinesia: Improving Patient Care
Locked Up in My Own Mind: Challenges in the Criminal Justice System
Psych Congress Action CenterLocked Up in My Own Mind: Challenges in the Criminal Justice System
- advertisement
Clarity for Schizophrenia: The Latest in Drug Treatment
Psych Congress Action CenterClarity for Schizophrenia: The Latest in Drug Treatment
Brian P. McDonough, MD, FAAFP
New Drug Approved for PPD: Solving an Unmet Need
NeuroFrontiersNew Drug Approved for PPD: Solving an Unmet Need
